The market for trastuzumab in the US is becoming increasingly crowded with Merck & Co. today launching Samsung Bioepis’ Ontruzant (trastuzumab-dttb) in two strengths, representing the fifth biosimilar to Genentech’s Herceptin available in the country, at a discount competitive with those offered by several other biosimilar players.
Merck’s approval and launch of the biosimilar, which marks Samsung Bioepis’ first oncology biosimilar in the US, spans all eligible...






